RT Journal Article
SR Electronic
T1 Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis: a mathematical modeling analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.07.28.23293104
DO 10.1101/2023.07.28.23293104
A1 James, Lyndon P.
A1 Klaassen, Fayette
A1 Sweeney, Sedona
A1 Furin, Jennifer
A1 Franke, Molly F.
A1 Yaesoubi, Reza
A1 Chesov, Dumitru
A1 Ciobanu, Nelly
A1 Codreanu, Alexandru
A1 Crudu, Valeriu
A1 Cohen, Ted
A1 Menzies, Nicolas A.
YR 2024
UL http://medrxiv.org/content/early/2024/01/31/2023.07.28.23293104.abstract
AB Background Emerging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment outcomes to longer regimens. We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) to a standard of care strategy using a 9- or 18-month regimen depending on whether fluoroquinolone resistance (FQ-R) is detected on Drug Susceptibility Testing (DST).Methods and Findings The primary objective was to determine whether 6 months of BPaLM is a cost-effective treatment strategy for RR-TB. We used genomic and demographic data to parameterize a mathematical model estimating long-term health outcomes measured in quality-adjusted life years (QALYs) and lifetime costs in 2022 USD ($) for each treatment strategy for patients 15 years and older diagnosed with pulmonary RR-TB in Moldova, a country with a high burden of TB drug resistance. For each individual, we simulated the natural history of TB and associated treatment outcomes, as well as the process of acquiring resistance to each of 12 anti-TB drugs. Compared to the standard of care, 6 months of BPaLM was cost-effective. It was estimated to reduce lifetime costs by $3,366 (95% UI: [1465, 5742] p<0.001) per individual, with a non-significant change in QALYs (−0.06; 95% UI: [-0.49, 0.032] p=0.790). For those stopping moxifloxacin under the BPaLM regimen, continuing with BPaL plus clofazimine (BPaLC) provided more QALYs at lower cost than continuing with BPaL alone. 6 months of BPaLM had at least a 93% chance of being cost-effective, so long as BPaLC was continued in the event of stopping moxifloxacin. 6 months of BPaLM reduced the average time spent with TB resistant to amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin and pyrazinamide, while it increased the average time spent with TB resistant to delamanid and pretomanid. Sensitivity analyses showed 6 months of BPaLM to be cost-effective across a broad range of values for the relative effectiveness of BPaLM, and the proportion of the cohort with FQ-R. Compared to the standard of care, 6 months of BPaLM would be expected to save Moldova’s national TB program budget $7.1 million (95% UI: [1.3 million, 15.4 million] p=0.002) over the five year period from implementation. This analysis did not account for all possible interactions between specific drugs as they apply to treatment effectiveness, to resistance acquisition, or to the consequences of specific types of severe adverse events, nor did it model how the intervention may affect the transmission dynamics of RR-TB.Conclusions Compared to the standard of care, the implementation of the 6-month BPaLM regimen could improve the cost-effectiveness of care for individuals diagnosed with RR-TB, particularly in settings where current long-course regimens are challenging to implement and afford. Further research may be warranted to explore the suitability of shorter RR-TB regimens in specific national settings.AUTHOR SUMMARY Why was this study done?Drug resistance poses a major barrier to the effective treatment of tuberculosis, especially in Moldova and other post-Soviet states which have the highest levels of resistance in the world.Individuals with tuberculosis resistant to the key drug rifampicin face a worse prognosis, a longer and more expensive course of treatment, and more side effects than individuals with rifampicin-susceptible tuberculosis.Until recently, the standard of care for rifampicin-resistant tuberculosis involved many drugs in combination, often given for 18 months or longer.The newer, 6-month “BPaLM” regimen is comprised of four drugs (bedaquiline, pretomanid, linezolid, moxifloxacin) to which resistance levels are currently low, and while it was shown to be just as effective as the standard of care for 72-week health outcomes, its effect on lifetime health outcomes, costs, and the acquisition of drug resistance was less clear.What did the researchers do and find?Using a mathematical model, we projected the lifetime health benefits and costs of the 6-month BPaLM regimen as compared to the standard of care treatments for rifampicin-resistant tuberculosis, and found that 6 months of BPaLM provided similar health benefits to longer regimens, at lower cost.Compared to the standard of care, we also found that the 6-month BPaLM regimen shortened the average duration of tuberculosis that was resistant to the drugs amikacin, bedaquiline, clofazimine, cycloserine, moxifloxacin, and pyrazinamide, while it increased the average duration of tuberculosis resistant to delamanid and pretomanid.For individuals receiving BPaLM who had to stop taking the drug moxifloxacin, we found that it would be beneficial on both health and cost grounds to replace it with clofazimine, thereby topping the regimen back up to four drugs.What do these findings mean?Using conventional benchmarks for value-for-money, 6 months of BPaLM is a cost-effective approach for the treatment of rifampicin-resistant tuberculosis in Moldova, and potentially other post-Soviet countries.Though the effect of the 6-month BPaLM regimen on the spread of drug resistance in the population is uncertain and not addressed directly by this study, this combination of newer drugs appears to achieve cure more quickly, which reduces the amount of time an individual is potentially infectious and so may be beneficial in fighting resistance to several drugs, even while it may increase the spread of resistance to others.Further studies may be warranted to explore how well these findings translate to different global regions where health system capabilities, costs, and existing resistance patterns may differ.Competing Interest StatementJF has received grant funding from the Stop TB Partnership Global Drug Facility to support the roll out of child-friendly formulations of second-line TB drugs.Funding StatementThis publication was made possible by Grant Numbers T32 AI007433 and R01 AI146555-02 from the National Institute of Allergy and Infectious Diseases. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Mycobacterium tuberculosis genomic data have been made openly available through GenBank at https://www.ncbi.nlm.nih.gov/bioproject/PRJNA736718I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are either contained in the manuscript or are available upon reasonable request to the authors. https://www.ncbi.nlm.nih.gov/bioproject/PRJNA736718 https://github.com/lyndonpjames/BPaLM_Moldova BPaLbedaquiline, pretomanid, linezolidBPaLCbedaquiline, pretomanid, linezolid, clofazimineBPaLMbedaquiline, pretomanid, linezolid, moxifloxacinCDFcumulative distribution functionCIconfidence intervalCrIcredibility intervalCPIConsumer Price IndexDSTdrug susceptibility testingFQ-Rfluoroquinolone-resistantFQ-Sfluoroquinolone-susceptibleLJLowenstein-JensenMDLMoldovan LeuGDPGross Domestic ProductGELGeorgian LeiHIVhuman immunodeficiency virusLTFUlost to follow upLYLife YearM. tb.Mycobacterium tuberculosisMDR-TBmultidrug-resistant tuberculosisNHBNet Health BenefitQALYQuality-adjusted Life YearRR-TBrifampicin-resistant tuberculosisSAEgrade 4-5 Severe Adverse EventSEMStandard Error of the MeanSMRstandardized mortality ratioTBtuberculosisUIUncertainty IntervalUSDUnited States DollarsWTPWillingness-to-PayXDR-TBextensively drug-resistant tuberculosis